

Ref. No: 485250122
From: Commercial
Date: 25/01/22
Subject: Usage of intra-vitreous injections or implants

REQUEST

I am analysing the usage of **intra-vitreous injections or implants** by the NHS. I would greatly appreciate if you could answer the following questions:

1. For the 4-month period from September to December 2021, how many patients has your trust treated (using intra-vitreous injections or implants) for each of the following eye conditions:

- Wet Age-Related Macular Degeneration (wAMD)
- Diabetic Macular Oedema (DMO)
- Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)
- Any other eye condition

2. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2021:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizumab

RESPONSE

Question 1.

For the 4-month period from September to December 2021, how many patients has your trust treated (using intra-vitreous injections or implants) for each of the following eye conditions:

- Wet Age-Related Macular Degeneration (wAMD) **753**
- Diabetic Macular Oedema (DMO) **175**
- Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO) **222**
- Any other eye condition **69**

Question 2

Drug Name	Quantity issued from Pharmacy
Aflibercept	515
Bevacizumab	0
Brolucizumab	11
Dexamethasone	52
Fluocinolone acetonide	0
Ranibizumab	797